Melanoma News and Research

Latest Melanoma News and Research

Researchers develop new way to identify potential therapeutic targets for drug resistant melanoma

Moffitt Cancer Center researchers developed a new way to identify possible therapeutic targets for patients with drug resistant melanoma. It involves using liquid chromatography-multiple reaction monitoring mass spectrometry to measure biomarkers or molecules in blood and tissue that indicates cancer is present. These measurements can help researchers determine if a patient is responding to treatment.

1 Jul 2014

EMA accepts for review Merck’s pembrolizumab MAA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for pembrolizumab (MK-3475), the company's investigational anti-PD-1 antibody, for the treatment of advanced melanoma.

30 Jun 2014

CNIO researchers identify over 40 genes that predict aggressiveness of melanoma

Researchers from the Spanish National Cancer Research Centre have discovered more than 40 genes that predict the level of aggressiveness of melanoma and that distinguish it from other cancers with a poor prognosis. The discovery, published in Cancer Cell, will help to identify unique aspects of melanoma that could contribute to determine the risk of developing metastasis in patients with this disease.

28 Jun 2014

Applying math to study cell migration and dynamics of organisms

Cell migration, which is involved in wound healing, cancer and tumor growth, and embryonic growth and development, has been a topic of interest to mathematicians and biologists for decades.

26 Jun 2014

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV nanocells packaged with doxorubicin for the treatment of recurrent glioblastoma (GBM), a common and aggressive type of brain tumor.

26 Jun 2014

Key historical misconceptions hinder research and treatment for brain metastases

"Key historical misconceptions" are hindering progress in research and treatment for patients with cancer metastases to the brain, suggests a special article in the July issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

25 Jun 2014

Study: Cohesin mutations are common in melanoma and bladder cancer

Massive sequencing of cancer genomes brings to light new genes every day that could be involved in the process of tumour formation.

25 Jun 2014

Scientists discover major breakthrough in cancer treatment

Scientists at the Sahlgrenska Academy, University of Gothenburg, have developed a new cancer treatment that has proved to be effective in mice. The treatment, which is presented in the prestigious scientific journal PNAS, is based on newly discovered properties of the so-called BET bromodomain inhibitors.

20 Jun 2014

Clinical trial shows that selumetinib drug can delay progression of metastatic uveal melanoma

For the first time, a therapy has been found that can delay progression of metastatic uveal melanoma, a rare and deadly form of melanoma of the eye.

20 Jun 2014

Melanoma in adulthood can be reduced by consistent use of sunscreen in childhood

Research conducted at the Texas Biomedical Research Institute, published in the latest issue of the scientific journal Pigment Cell and Melanoma, has established unequivocally in a natural animal model that the incidence of malignant melanoma in adulthood can be dramatically reduced by the consistent use of sunscreen in infancy and childhood.

20 Jun 2014

Clinically relevant mouse model for difficult-to-treat squamous cell lung cancer

Only 15% of patients with squamous cell lung cancer - the second most common lung cancer - survive five years past diagnosis.

20 Jun 2014

Novogen, CanTx believe Intra-Peritoneal Trx-1 could be utilized as first-line therapy for ovarian cancer

Australian oncology drug development company Novogen Limited and CanTx Inc., its joint venture with Yale University, today announced the success of proof-of-concept pre-clinical studies confirming the potency of experimental drug, Trx-1, in the treatment of primary ovarian cancer when delivered into the peritoneal cavity.

18 Jun 2014

Western Oncolytics closes $275,000 in seed funding

Western Oncolytics Ltd., a biotech company specializing in immuno-oncolytic cancer therapies, has closed $275,000 in seed funding. The proceeds are planned to set a path toward clinical trials and execute initial manufacturing for its novel virus-based cancer therapy, which delivers genes to guide the immune system to kill cancer cells.

18 Jun 2014

Study compares effectiveness of selumetinib, chemotherapy in patients with advanced uveal melanoma

In patients with advanced uveal melanoma, treatment with the agent selumetinib, compared with chemotherapy, resulted in an improved cancer progression-free survival time and tumor response rate, but no improvement in overall survival, according to a study in the June 18 issue of JAMA. The modest improvement in clinical outcomes was accompanied by a high rate of adverse events.

18 Jun 2014

Six essential screening tests all men should receive during lifetime

When it's comes men and health, the numbers don't stack up. Compared to women, men are 24 percent less likely than women to visit the doctor, according to the U.S. Department of Health & Human Services. Yet, men are 28 percent more likely than women to be hospitalized for congestive heart failure and 32 percent more likely to receive care for complication of diabetes.

17 Jun 2014

Trovagene enters into clinical collaboration with Dana-Farber Cancer Institute

Trovagene, Inc. today announced that it has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time in metastatic melanoma patients.

16 Jun 2014

FDA approves use for Lymphoseek to help doctors determine extent of neck and cancer

The U.S. Food and Drug Administration today approved a new use for Lymphoseek (technetium 99m tilmanocept) Injection, a radioactive diagnostic imaging agent used to help doctors determine the extent a type of cancer called squamous cell carcinoma has spread in the body's head and neck region.

16 Jun 2014

Melanoma News and Research

Latest Melanoma News and Research

Researchers develop new way to identify potential therapeutic targets for drug resistant melanoma

EMA accepts for review Merck’s pembrolizumab MAA for treatment of advanced melanoma

CNIO researchers identify over 40 genes that predict aggressiveness of melanoma

Applying math to study cell migration and dynamics of organisms

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

Key historical misconceptions hinder research and treatment for brain metastases

Study: Cohesin mutations are common in melanoma and bladder cancer

Scientists discover major breakthrough in cancer treatment

Clinical trial shows that selumetinib drug can delay progression of metastatic uveal melanoma

Melanoma in adulthood can be reduced by consistent use of sunscreen in childhood

Clinically relevant mouse model for difficult-to-treat squamous cell lung cancer

Novogen, CanTx believe Intra-Peritoneal Trx-1 could be utilized as first-line therapy for ovarian cancer

Western Oncolytics closes $275,000 in seed funding

Study compares effectiveness of selumetinib, chemotherapy in patients with advanced uveal melanoma

Six essential screening tests all men should receive during lifetime

Trovagene enters into clinical collaboration with Dana-Farber Cancer Institute

FDA approves use for Lymphoseek to help doctors determine extent of neck and cancer

New class of tumor-targeting agents can seek out dozens of solid tumors

Hunterdon Regional Cancer Center offers immuno-therapy clinical trial for lung cancer

New framework for monitoring oral cancer development, progression, recurrence

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Melanoma News and Research

Latest Melanoma News and Research

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in